ArticleBiotechnology for biofuels2015
Development of cellobiose-degrading ability in Yarrowia lipolytica strain by overexpression of endogenous genes.
Article in Biotechnology for biofuels, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 69 citations in OpenAlex.
- Expression of a periplasmic β-glucosidase from Yarrowia lipolytica allows efficient cellobiose-xylose co-fermentation by industrial xylose-fermenting Saccharomyces cerevisiae strains.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Proteomic insights into the physiology and metabolism of oleaginous yeasts and filamentous fungi.Frontiers in microbiology · 2025Review
- Installing xylose assimilation and cellodextrin phosphorolysis pathways in obese Yarrowia lipolytica facilitates cost-effective lipid production from lignocellulosic hydrolysates.Biotechnology for biofuels and bioproducts · 2023Article
- Biotechnological production of omega-3 fatty acids: current status and future perspectives.Frontiers in microbiology · 2023Review
- Biocontrol of Non-Microorganisms · 2022Article
- Efficient production of the β-ionone aroma compound from organic waste hydrolysates using an engineeredFrontiers in microbiology · 2022Article
- Yarrowia lipolytica chassis strains engineered to produce aromatic amino acids via the shikimate pathway.Microbial biotechnology · 2021Article
- Consolidated Bioprocessing: Synthetic Biology Routes to Fuels and Fine Chemicals.Microorganisms · 2021Review
- Disruption of theFrontiers in microbiology · 2021Article
- Methods to Activate and Elucidate Complex Endogenous Sugar Metabolism in Yarrowia lipolytica.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Secretion of a low and high molecular weight β-glycosidase by Yarrowia lipolytica.Microbial cell factories · 2020Article
- An artificial chromosome ylAC enables efficient assembly of multiple genes in Yarrowia lipolytica for biomanufacturing.Communications biology · 2020Article
- Advances and opportunities in gene editing and gene regulation technology for Yarrowia lipolytica.Microbial cell factories · 2019Review
- Organic Wastes as Feedstocks for Non-Conventional Yeast-Based Bioprocesses.Microorganisms · 2019Review
- Article
- Synthetic biology tools for engineering Yarrowia lipolytica.Biotechnology advances · 2018Review
- Engineering Yarrowia lipolytica for Use in Biotechnological Applications: A Review of Major Achievements and Recent Innovations.Molecular biotechnology · 2018Review
- Engineering the oleaginous red yeast Rhodotorula glutinis for simultaneous β-carotene and cellulase production.Scientific reports · 2018Article
- Alternative Substrate Metabolism inFrontiers in microbiology · 2018Review
- Ameliorating the Metabolic Burden of the Co-expression of Secreted Fungal Cellulases in a High Lipid-AccumulatingFrontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYarrowia lipolytica, one of the most widely studied "nonconventional" oleaginous yeast species, is unable to grow on cellobiose. Engineering cellobiose-degrading ability into this yeast is a vital step towards the development of cellulolytic biocatalysts suitable for consolidated bioprocessing.
resultsIn the present work, we identified six genes encoding putative β-glucosidases in the Y. lipolytica genome. To study these, homologous expression was attempted in Y. lipolytica JMY1212 Zeta. Two strains overexpressing BGL1 (YALI0F16027g) and BGL2 (YALI0B14289g) produced β-glucosidase activity and were able to degrade cellobiose, while the other four did not display any detectable activity. The two active β-glucosidases, one of which was mainly cell-associated while the other was present in the extracellular medium, were purified and characterized. The two Bgls were most active at 40-45°C and pH 4.0-4.5, and exhibited hydrolytic activity on various β-glycoside substrates. Specifically, Bgl1 displayed 12.5-fold higher catalytic efficiency on cellobiose than Bgl2. Significantly, in experiments where cellobiose or cellulose (performed in the presence of a β-glucosidase-deficient commercial cellulase cocktail produced by Trichoderma reseei) was used as carbon source for aerobic cultivation, Y. lipolytica ∆pox co-expressing BGL1 and BGL2 grew better than the Y. lipolytica strains expressing single BGLs. The specific growth rate and biomass yield of Y. lipolytica JMY1212 co-expressing BGL1 and BGL2 were 0.15 h(-1) and 0.50 g-DCW/g-cellobiose, respectively, similar to that of the control grown on glucose.
conclusionsWe conclude that the bi-functional Y. lipolytica developed in the current study represents a vital step towards the creation of a cellulolytic yeast strain that can be used for lipid production from lignocellulosic biomass. When used in combination with commercial cellulolytic cocktails, this strain will no doubt reduce enzyme requirements and thus costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.